BioCentury | Oct 21, 2020
Product Development

How COVID-19 challenge trials will be shaped by emerging data

...told BioCentury. “Challenge trials are advantageous because they may speed the comparative assessment of vaccines.”The hVIVO...
...be conducted together with The Royal Free Hospital in London. The U.K. government also paid hVIVO...
...in 2021, most likely after at least one first-generation candidate is already authorized for emergency use.hVIVO...
BioCentury | Jan 17, 2019
Clinical News

hVIVO reports Phase IIb data of universal flu vaccine

...vaccine in 2020. NIH's National Institute of Allergy and Infectious Diseases (NIAID), which collaborated with hVIVO...
...or placebo followed by intranasal challenge with a 2009 strain of H1N1 influenza A virus. hVIVO...
...Imutex Ltd. in 2016 to develop vaccines against the flu, including FLU-v, and mosquito-borne diseases. hVIVO...
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...which reached Phase I/II testing. (A) Imutex Ltd. is a JV between Seek Ltd. and hVIVO...
BioCentury | Mar 31, 2017
Clinical News

AGS-v: Ph I started

...an immune response to mosquito saliva, rather than a specific virus or parasite. Last year, hVIVO...
...develop AGS-v and FLU-v , a universal flu vaccine (see BioCentury, May 2, 2016 ). hVIVO...
...aegypti mosquito biting and mosquito behavior Status: Phase I started Milestone: Complete Phase I (mid-2018) Alex Himes hVIVO...
BioCentury | Feb 17, 2017
Clinical News

PrEP-001: Ph IIa PrEP-CS-003 data

...the time of first dosing to 8 days post-inoculation vs. placebo. PrEP-001 was well tolerated. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
...from peak symptoms, incidence of HRV infection and safety Status: Phase IIa data Milestone: NA Alicia Parker PrEP-001 hVIVO...
BioCentury | Feb 17, 2017
Clinical News

PrEP-001: Ph IIa PrEP-CS-002 data

...TSS score of 0 points, vs. placebo (26.3% vs. 0%, p=0.002). PrEP-001 was well tolerated. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
...symptoms, incidence of HRV infection, viral load and safety Status: Phase IIa data Milestone: NA Alicia Parker PrEP-001 hVIVO...
BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

...inhibitors of Zika viral replication Preclinical Undisclosed vaccine Emergent BioSolutions Inc. (NYSE:EBS) Undisclosed vaccine Preclinical hVIVO...
BioCentury | Sep 19, 2016
Clinical News

PrEP-001: Phase IIa data

...with influenza virus showed that nasal PrEP-001 reduced the number of flu symptoms vs. placebo. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
BioCentury | May 2, 2016
Company News

hVIVO, Seek Ltd. deal

...hVIVO will pay L7 million for a 49% stake in Imutex, and Seek will contract hVIVO...
...trial of a Zika vaccine “in the coming months.” hVIVO did not respond to inquiries. hVIVO...
BioCentury | Dec 7, 2015
Financial News

hVIVO proposes placing

hVIVO plc (LSE:HVO), London, U.K. Business: Supply/Service Date announced: 2015-11-26 Type: Placing To be raised: Up to L20.5 million ($31.1 million) Shares: 9.1 million Price: 225p Shares outstanding prior: 68.9 million Placement agent: Numis Investor:...
Items per page:
1 - 10 of 12
BioCentury | Oct 21, 2020
Product Development

How COVID-19 challenge trials will be shaped by emerging data

...told BioCentury. “Challenge trials are advantageous because they may speed the comparative assessment of vaccines.”The hVIVO...
...be conducted together with The Royal Free Hospital in London. The U.K. government also paid hVIVO...
...in 2021, most likely after at least one first-generation candidate is already authorized for emergency use.hVIVO...
BioCentury | Jan 17, 2019
Clinical News

hVIVO reports Phase IIb data of universal flu vaccine

...vaccine in 2020. NIH's National Institute of Allergy and Infectious Diseases (NIAID), which collaborated with hVIVO...
...or placebo followed by intranasal challenge with a 2009 strain of H1N1 influenza A virus. hVIVO...
...Imutex Ltd. in 2016 to develop vaccines against the flu, including FLU-v, and mosquito-borne diseases. hVIVO...
BioCentury | Feb 22, 2018
Product R&D

Shooting for the universe

...which reached Phase I/II testing. (A) Imutex Ltd. is a JV between Seek Ltd. and hVIVO...
BioCentury | Mar 31, 2017
Clinical News

AGS-v: Ph I started

...an immune response to mosquito saliva, rather than a specific virus or parasite. Last year, hVIVO...
...develop AGS-v and FLU-v , a universal flu vaccine (see BioCentury, May 2, 2016 ). hVIVO...
...aegypti mosquito biting and mosquito behavior Status: Phase I started Milestone: Complete Phase I (mid-2018) Alex Himes hVIVO...
BioCentury | Feb 17, 2017
Clinical News

PrEP-001: Ph IIa PrEP-CS-003 data

...the time of first dosing to 8 days post-inoculation vs. placebo. PrEP-001 was well tolerated. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
...from peak symptoms, incidence of HRV infection and safety Status: Phase IIa data Milestone: NA Alicia Parker PrEP-001 hVIVO...
BioCentury | Feb 17, 2017
Clinical News

PrEP-001: Ph IIa PrEP-CS-002 data

...TSS score of 0 points, vs. placebo (26.3% vs. 0%, p=0.002). PrEP-001 was well tolerated. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
...symptoms, incidence of HRV infection, viral load and safety Status: Phase IIa data Milestone: NA Alicia Parker PrEP-001 hVIVO...
BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

...inhibitors of Zika viral replication Preclinical Undisclosed vaccine Emergent BioSolutions Inc. (NYSE:EBS) Undisclosed vaccine Preclinical hVIVO...
BioCentury | Sep 19, 2016
Clinical News

PrEP-001: Phase IIa data

...with influenza virus showed that nasal PrEP-001 reduced the number of flu symptoms vs. placebo. hVIVO...
...with PrEP, which has an exclusive, worldwide license to the compound from Johnson & Johnson. hVIVO...
BioCentury | May 2, 2016
Company News

hVIVO, Seek Ltd. deal

...hVIVO will pay L7 million for a 49% stake in Imutex, and Seek will contract hVIVO...
...trial of a Zika vaccine “in the coming months.” hVIVO did not respond to inquiries. hVIVO...
BioCentury | Dec 7, 2015
Financial News

hVIVO proposes placing

hVIVO plc (LSE:HVO), London, U.K. Business: Supply/Service Date announced: 2015-11-26 Type: Placing To be raised: Up to L20.5 million ($31.1 million) Shares: 9.1 million Price: 225p Shares outstanding prior: 68.9 million Placement agent: Numis Investor:...
Items per page:
1 - 10 of 12